STOCK TITAN

[Form 3] Rafael Holdings, Inc. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

Joshua M. Fine, Chief Operations Officer of Rafael Holdings, Inc. (RFL), filed a Form 3 reporting ownership following an event dated 08/04/2025. He holds 9,380 Class B common shares (held jointly with his wife) and stock options totaling 137,881 shares from five grants exercisable 2021–2025 with exercise prices ranging from $1.00 to $21.16. The shares and options were received or converted in connection with the business combination with Cyclo Therapeutics on March 25, 2025.

Joshua M. Fine, Chief Operations Officer di Rafael Holdings, Inc. (RFL), ha presentato un Form 3 per segnalare la propria partecipazione in relazione a un evento datato 08/04/2025. Detiene 9,380 azioni ordinarie di classe B (in comunione con la moglie) e stock option per un totale di 137,881 azioni derivanti da cinque assegnazioni esercitabili tra il 2021 e il 2025, con prezzi di esercizio compresi tra $1.00 e $21.16. Le azioni e le opzioni sono state ricevute o convertite in relazione alla combinazione aziendale con Cyclo Therapeutics il 25 marzo 2025.

Joshua M. Fine, Director de Operaciones (Chief Operations Officer) de Rafael Holdings, Inc. (RFL), presentó un Formulario 3 notificando su participación tras un hecho fechado el 08/04/2025. Posee 9,380 acciones ordinarias Clase B (en copropiedad con su esposa) y opciones sobre acciones por un total de 137,881 acciones procedentes de cinco concesiones ejercitables entre 2021 y 2025, con precios de ejercicio que van de $1.00 a $21.16. Las acciones y las opciones fueron recibidas o convertidas en relación con la combinación empresarial con Cyclo Therapeutics el 25 de marzo de 2025.

Joshua M. Fine는 Rafael Holdings, Inc. (RFL)의 최고운영책임자(Chief Operations Officer)로서 08/04/2025자 사건과 관련해 소유를 신고하는 Form 3를 제출했습니다. 그는 배우자와 공동 보유 중인 9,380주의 클래스 B 보통주와 2021년부터 2025년까지 행사 가능한 다섯 건의 부여에서 나온 총 137,881주의 스톡옵션을 보유하고 있으며, 행사가격은 $1.00~$21.16입니다. 해당 주식과 옵션은 2025년 3월 25일 Cyclo Therapeutics와의 기업 결합과 관련하여 수령되거나 전환되었습니다.

Joshua M. Fine, Chief Operations Officer de Rafael Holdings, Inc. (RFL), a déposé un formulaire 3 déclarant sa participation suite à un événement daté du 08/04/2025. Il détient 9 380 actions ordinaires de classe B (en indivision avec son épouse) et des options d'achat totalisant 137 881 actions issues de cinq attributions exerçables entre 2021 et 2025, avec des prix d'exercice allant de 1,00 $ à 21,16 $. Les actions et options ont été reçues ou converties dans le cadre de la fusion avec Cyclo Therapeutics le 25 mars 2025.

Joshua M. Fine, Chief Operations Officer von Rafael Holdings, Inc. (RFL), reichte ein Form 3 ein, um seinen Besitz im Zusammenhang mit einem Ereignis vom 08/04/2025 zu melden. Er hält 9.380 Class‑B‑Stammaktien (gemeinsam mit seiner Ehefrau) und Aktienoptionen im Gesamtumfang von 137.881 Aktien aus fünf Zuteilungen, die in den Jahren 2021–2025 ausübbar sind, mit Ausübungspreisen zwischen $1.00 und $21.16. Die Aktien und Optionen wurden im Zusammenhang mit der Unternehmenszusammenführung mit Cyclo Therapeutics am 25. März 2025 erhalten oder umgewandelt.

Positive
  • Form 3 disclosure explicitly reports 9,380 Class B shares and detailed option grants, improving transparency for investors.
  • Holdings were received/converted in connection with the business combination with Cyclo Therapeutics on March 25, 2025, which the filing documents.
Negative
  • None.

Insights

TL;DR Routine insider disclosure: COO reports direct holdings of shares and multiple option grants tied to the Cyclo combination.

The Form 3 provides a clear, itemized record of Mr. Fine's direct beneficial ownership: 9,380 Class B shares and five option grants totaling 137,881 underlying shares with exercise prices from $1.00 to $21.16. The disclosure is standard post-transaction reporting and allows investors to quantify insider exposure and potential future dilution from exercisable options.

TL;DR Filing documents insider holdings after a merger; disclosure appears complete and timely for a Form 3.

The filing identifies Mr. Fine as the Chief Operations Officer and reports both direct share ownership (jointly held) and direct option holdings. It states the provenance of the securities as conversion/receipt in the business combination with Cyclo on March 25, 2025. The form is signed by a power of attorney on 08/11/2025, consistent with routine administrative handling of insider filings.

Joshua M. Fine, Chief Operations Officer di Rafael Holdings, Inc. (RFL), ha presentato un Form 3 per segnalare la propria partecipazione in relazione a un evento datato 08/04/2025. Detiene 9,380 azioni ordinarie di classe B (in comunione con la moglie) e stock option per un totale di 137,881 azioni derivanti da cinque assegnazioni esercitabili tra il 2021 e il 2025, con prezzi di esercizio compresi tra $1.00 e $21.16. Le azioni e le opzioni sono state ricevute o convertite in relazione alla combinazione aziendale con Cyclo Therapeutics il 25 marzo 2025.

Joshua M. Fine, Director de Operaciones (Chief Operations Officer) de Rafael Holdings, Inc. (RFL), presentó un Formulario 3 notificando su participación tras un hecho fechado el 08/04/2025. Posee 9,380 acciones ordinarias Clase B (en copropiedad con su esposa) y opciones sobre acciones por un total de 137,881 acciones procedentes de cinco concesiones ejercitables entre 2021 y 2025, con precios de ejercicio que van de $1.00 a $21.16. Las acciones y las opciones fueron recibidas o convertidas en relación con la combinación empresarial con Cyclo Therapeutics el 25 de marzo de 2025.

Joshua M. Fine는 Rafael Holdings, Inc. (RFL)의 최고운영책임자(Chief Operations Officer)로서 08/04/2025자 사건과 관련해 소유를 신고하는 Form 3를 제출했습니다. 그는 배우자와 공동 보유 중인 9,380주의 클래스 B 보통주와 2021년부터 2025년까지 행사 가능한 다섯 건의 부여에서 나온 총 137,881주의 스톡옵션을 보유하고 있으며, 행사가격은 $1.00~$21.16입니다. 해당 주식과 옵션은 2025년 3월 25일 Cyclo Therapeutics와의 기업 결합과 관련하여 수령되거나 전환되었습니다.

Joshua M. Fine, Chief Operations Officer de Rafael Holdings, Inc. (RFL), a déposé un formulaire 3 déclarant sa participation suite à un événement daté du 08/04/2025. Il détient 9 380 actions ordinaires de classe B (en indivision avec son épouse) et des options d'achat totalisant 137 881 actions issues de cinq attributions exerçables entre 2021 et 2025, avec des prix d'exercice allant de 1,00 $ à 21,16 $. Les actions et options ont été reçues ou converties dans le cadre de la fusion avec Cyclo Therapeutics le 25 mars 2025.

Joshua M. Fine, Chief Operations Officer von Rafael Holdings, Inc. (RFL), reichte ein Form 3 ein, um seinen Besitz im Zusammenhang mit einem Ereignis vom 08/04/2025 zu melden. Er hält 9.380 Class‑B‑Stammaktien (gemeinsam mit seiner Ehefrau) und Aktienoptionen im Gesamtumfang von 137.881 Aktien aus fünf Zuteilungen, die in den Jahren 2021–2025 ausübbar sind, mit Ausübungspreisen zwischen $1.00 und $21.16. Die Aktien und Optionen wurden im Zusammenhang mit der Unternehmenszusammenführung mit Cyclo Therapeutics am 25. März 2025 erhalten oder umgewandelt.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Fine Joshua M

(Last) (First) (Middle)
C/O RAFAEL HOLDINGS, INC.
520 BROAD STREET

(Street)
NEWARK NJ 07102

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
08/04/2025
3. Issuer Name and Ticker or Trading Symbol
Rafael Holdings, Inc. [ RFL ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operations Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Class B Common Stock, $.01 par value per share 9,380(1)(2) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) 08/30/2021 08/30/2031 Class B Common Stock 8,389(2) $21.16 D
Stock Option (right to buy) 02/28/2022 02/28/2032 Class B Common Stock 10,997(2) $9.25 D
Stock Option (right to buy) 03/02/2023 03/01/2033 Class B Common Stock 14,464(2) $3.63 D
Stock Option (right to buy) 06/03/2024 06/03/2034 Class B Common Stock 39,031(2) $3.63 D
Stock Option (right to buy) 03/25/2025 03/25/2035 Class B Common Stock 65,000 $1 D
Explanation of Responses:
1. Consists of 9,380 shares of Class B common stock held jointly by the Reporting Person and his wife
2. The shares, options and warrants were all received in exchange for shares, options and warrants, respectively, of Cyclo Therapeutics, Inc. ("Cyclo") common stock and upon conversion of options and warrants to purchase shares of Cyclo common stock in connection with the business combination between the Issuer and Cyclo on March 25, 2025.
Joyce J Mason, by Power of Attorney 08/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Joshua M. Fine report on Form 3 for Rafael Holdings (RFL)?

He reported ownership of 9,380 Class B common shares (held jointly with his wife) and stock options totaling 137,881 shares across five grants; event dated 08/04/2025.

How many stock options and what exercise prices were disclosed on the RFL Form 3?

Five option grants totaling 137,881 underlying shares with exercise prices of $21.16, $9.25, $3.63, $3.63, and $1.00.

Are the reported securities held directly or indirectly?

The filing indicates Direct (D) ownership for the Class B shares and for the option holdings; the 9,380 shares are held jointly with his wife.

When were the reported securities received or converted?

The filing states the shares, options and warrants were received or converted in connection with the business combination with Cyclo Therapeutics on March 25, 2025.

Who signed the Form 3 and when was it signed?

The Form 3 was signed by Joyce J Mason, by Power of Attorney on 08/11/2025.
Rafael Holdings

NYSE:RFL

RFL Rankings

RFL Latest News

RFL Latest SEC Filings

RFL Stock Data

46.69M
15.19M
55.75%
10.92%
0.13%
Real Estate Services
Pharmaceutical Preparations
Link
United States
NEWARK